212 related articles for article (PubMed ID: 10955783)
21. Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2.
van Dongen GA; Leverstein H; Roos JC; Quak JJ; van den Brekel MW; van Lingen A; Martens HJ; Castelijns JA; Visser GW; Meijer CJ
Cancer Res; 1992 May; 52(9):2569-74. PubMed ID: 1568225
[TBL] [Abstract][Full Text] [Related]
22. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Nestor M; Ekberg T; Dring J; van Dongen GA; Wester K; Tolmachev V; Anniko M
Tumour Biol; 2007; 28(5):253-63. PubMed ID: 17992053
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution of 131I-labeled anti-CK8 monoclonal antibody in HNSCC in xenotransplanted SCID mice.
Andratschke M; Luebbers CW; Johannson V; Schmitt B; Mack B; Zeidler R; Lang S; Wollenberg B; Gildehaus FJ
Anticancer Res; 2011 Oct; 31(10):3315-21. PubMed ID: 21965741
[TBL] [Abstract][Full Text] [Related]
24. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
25. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.
van Hal NL; van Dongen GA; Stigter-van Walsum M; Snow GB; Brakenhoff RH
Int J Cancer; 1999 Sep; 82(6):837-45. PubMed ID: 10446451
[TBL] [Abstract][Full Text] [Related]
26. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
27. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
Soukka T; Salmi M; Joensuu H; Häkkinen L; Sointu P; Koulu L; Kalimo K; Klemi P; Grénman R; Jalkanen S
Cancer Res; 1997 Jun; 57(11):2281-9. PubMed ID: 9187133
[TBL] [Abstract][Full Text] [Related]
28. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
Heuveling DA; de Bree R; Vugts DJ; Huisman MC; Giovannoni L; Hoekstra OS; Leemans CR; Neri D; van Dongen GA
J Nucl Med; 2013 Mar; 54(3):397-401. PubMed ID: 23334725
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
Sauter A; Kloft C; Gronau S; Bogeschdorfer F; Erhardt T; Golze W; Schroen C; Staab A; Riechelmann H; Hoermann K
Int J Oncol; 2007 Apr; 30(4):927-35. PubMed ID: 17332932
[TBL] [Abstract][Full Text] [Related]
30. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.
Heider KH; Sproll M; Susani S; Patzelt E; Beaumier P; Ostermann E; Ahorn H; Adolf GR
Cancer Immunol Immunother; 1996 Dec; 43(4):245-53. PubMed ID: 9003471
[TBL] [Abstract][Full Text] [Related]
32. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
34. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
37. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract.
De Bree R; Roos JC; Quak JJ; Den Hollander W; Snow GB; Van Dongen GA
Nucl Med Commun; 1994 Aug; 15(8):613-27. PubMed ID: 7970443
[TBL] [Abstract][Full Text] [Related]
38. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies.
Klivényi G; Schuhmacher J; Patzelt E; Hauser H; Matys R; Moock M; Regiert T; Maier-Borst W
J Nucl Med; 1998 Oct; 39(10):1769-76. PubMed ID: 9776285
[TBL] [Abstract][Full Text] [Related]
39. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.
van Gog FB; Brakenhoff RH; Snow GB; van Dongen GA
Cancer Immunol Immunother; 1997 Apr; 44(2):103-11. PubMed ID: 9177472
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
